Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
24.64
+0.35 (1.44%)
At close: Apr 7, 2026, 4:00 PM EDT
24.98
+0.34 (1.38%)
Pre-market: Apr 8, 2026, 7:37 AM EDT
Syndax Pharmaceuticals Revenue
In the year 2025, Syndax Pharmaceuticals had annual revenue of $172.35M with 627.84% growth. Syndax Pharmaceuticals had revenue of $68.73M in the quarter ending December 31, 2025, with 794.90% growth.
Revenue (ttm)
$172.60M
Revenue Growth
+628.88%
P/S Ratio
12.61
Revenue / Employee
$578,362
Employees
298
Market Cap
2.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 172.35M | 148.67M | 627.84% |
| Dec 31, 2024 | 23.68M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 139.71M | 138.19M | 9,109.56% |
| Dec 31, 2020 | 1.52M | - | - |
| Dec 31, 2019 | 1.52M | - | - |
| Dec 31, 2018 | 1.52M | -591.00K | -28.04% |
| Dec 31, 2017 | 2.11M | 888.00K | 72.79% |
| Dec 31, 2016 | 1.22M | 593.00K | 94.58% |
| Dec 31, 2015 | 627.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 673.00M |
| ADMA Biologics | 510.17M |
| Aurinia Pharmaceuticals | 283.06M |
| Adaptive Biotechnologies | 276.98M |
| Day One Biopharmaceuticals | 158.18M |
| Nektar Therapeutics | 55.23M |
| Agios Pharmaceuticals | 54.03M |
SNDX News
- 4 days ago - Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Syndax Announces Participation in March Investor Conferences - GlobeNewsWire
- 6 weeks ago - Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - GlobeNewsWire
- 2 months ago - Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit - GlobeNewsWire
- 3 months ago - Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S. - GlobeNewsWire
- 3 months ago - Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire